News Snapshot:
Coronavirus company news summary â Tonix Pharmaceuticals developing drug for long Covid symptoms â Vaxxinity and Ubi-Asia sign vaccine purchase agreement with Paraguay 22 Jun 2021 (Last Updated June 22nd, 2021 09:20) Share Article Tonix Pharmaceuticals , a clinical-stage biopharmaceutical company, is planning on developing TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to treat long Covid or post-acute sequelae of Covid-19 (PASC1). Tonix is expected to meet with the US Food and Drug Administration in the third quarter of 2021 to agree on a potential Phase II pivotal study and the clinical development of TNX-102 SL for long Covid treatment. TNX-102...
